Skip to content

A multicenter randomized controlled clinical study on the treatment of cough variant asthma (phlegm heat accumulation in the lungs) in children with pediatric cough granules

A multicenter randomized controlled clinical study on the treatment of cough variant asthma (phlegm heat accumulation in the lungs) in children with pediatric cough granules

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086509
Enrollment
Unknown
Registered
2024-07-03
Start date
2024-04-13
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cough variant asthma

Interventions

Experimental group:Children's cough granules

Sponsors

Liaoning University of Traditional Chinese Medicine Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 13 Years

Inclusion criteria

Inclusion criteria: 1: Only those who meet all the following conditions in the study can be selected: (1) meet the Western medical diagnostic criteria for pediatric CVA; (2) The diagnostic criteria of traditional Chinese medicine conform to the syndrome of phlegm heat accumulation in the lungs; (3) Age range from 3 to 13 years old (<14 years old), no gender restrictions; (4) Must obtain the informed consent of the legal guardian of the subject and voluntarily sign the informed consent form; When the subject is able to make a decision to participate in a clinical trial, their consent must also be obtained.

Exclusion criteria

Exclusion criteria: 1: Those who meet any of the following criteria in the study need to be excluded: (1) post infection cough, cardiogenic cough, otogenic cough, eosinophilic bronchitis, gastroesophageal reflux cough, drug-induced cough, foreign body inhalation, congenital respiratory diseases, chronic cough caused by specific pathogens, persistent bronchitis, as well as children with allergic cough and simple upper airway cough syndrome; (2) Children who are allergic to the investigational drug and its components; (3) Patients with severe diseases of the heart, liver, kidney, blood, and other systems; (4) Individuals who have participated in other clinical trials three months prior to the trial; (5) Researchers believe that participants are not suitable for this clinical trial.

Design outcomes

Primary

MeasureTime frame
Traditional Chinese Medicine Syndrome Therapeutic Effect;

Secondary

MeasureTime frame
Disease control assessment;Improvement in cough severity;Quality of life;Asthma incidence;Other adverse events (AE) and serious adverse events (SAE);

Countries

China

Contacts

Public ContactWang Xuefeng

Liaoning University of Traditional Chinese Medicine Affiliated Hospital

lnzywxf@163.com+86 138 4020 8807

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026